Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Related Posts

Dell sees its backlog swell as big AI deals come through

Dell sees its backlog swell as big AI deals come through

Nvidia’s stock is in a funk. Earnings didn’t help, but here’s what could.

Nvidia’s stock is in a funk. Earnings didn’t help, but ...

HP Inc. was proactive about the impact of tariffs, and it may be paying off

HP Inc. was proactive about the impact of tariffs, and ...

Rocket Lab makes ‘bold’ satellite move, but shares slide on weak outlook

Rocket Lab makes ‘bold’ satellite move, but shares slid...

Autodesk says it’s cutting 9% of its workforce, and shares rise

Autodesk says it’s cutting 9% of its workforce, and sha...

Canada watchdog probing X's use of personal data in AI models' training

Canada watchdog probing X's use of personal data in AI ...